A5087877804- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Mobile Health and mHealth Applications
- Physical Activity and Health
- Esophageal and GI Pathology
- Obesity, Physical Activity, Diet
- Asthma and respiratory diseases
- Lung Cancer Diagnosis and Treatment
- Nutrition, Genetics, and Disease
- Health and Medical Studies
- Pharmaceutical studies and practices
- Multiple Myeloma Research and Treatments
- Eating Disorders and Behaviors
- Behavioral Health and Interventions
- Economic and Financial Impacts of Cancer
- Pain Management and Placebo Effect
- Medical Imaging Techniques and Applications
- Chemotherapy-related skin toxicity
- Clinical practice guidelines implementation
- Digital Mental Health Interventions
- Radiomics and Machine Learning in Medical Imaging
- Medical and Health Sciences Research
University Cancer Center Hamburg
2024
Universität Hamburg
2024
University Medical Center Hamburg-Eppendorf
2024
Universitätsmedizin Göttingen
2019-2022
University of Göttingen
2019-2021
University Medical Center Freiburg
2014
University of Freiburg
2014
Technical University of Munich
2006-2007
Klinikum rechts der Isar
2003-2007
Loyola University Chicago
2000
Oxaliplatin plus fluorouracil/folinic acid (5-FU/FA) every 2 weeks has shown promising activity in advanced gastric cancer. This study assessed the efficacy and safety of weekly oxaliplatin 5-FU/FA (FUFOX regimen) metastatic setting. Patients with previously untreated cancer received (50 mg m−2) FA (500 m−2, 2-h infusion) followed by 5-FU (2000 24-h given on days 1, 8, 15 22 a 5-week cycle. The primary end point this multicentre phase II was response rate according to RECIST criteria. A...
This phase II trial assessed the toxicity and efficacy of irinotecan plus docetaxel in cisplatin-pretreated oesophageal cancer. Irinotecan 160 mg m−2 65 once every 3 weeks led to severe myelosuppression four patients, all whom experienced neutropenic fever. After amendment this regimen, 24 patients (male/female=18/6; median age=58.5 years; ECOG performance status 0/1/2=9/11/4) with advanced cancer (adenocarcinoma/epidermoid carcinoma=13/11) received 55 25 on days 1, 8 15 a 28-day cycle....
Capecitabine and docetaxel have single-agent activity in upper gastrointestinal tumours, together demonstrated preclinical synergy a survival benefit breast cancer, high response rates first-line metastatic gastric cancer. This trial assessed the efficacy, safety feasibility of capecitabine combination with patients oesophageal In all, 24 advanced disease (17 squamous cell carcinoma seven adenocarcinoma) received oral (1000 mg m(-2) twice daily on days 1-14) plus intravenous (75 day 1) every...
Background Mobile health apps have great potential to support the self-management of chronic conditions such as allergic diseases, which constitute significant challenges in care. However, app market is confusing for users, it vast, dynamic, and lacks scientific evidence regarding effectiveness on offer. To our knowledge, no pollen-related rhinitis has been evaluated. Objective The aim study was evaluate Husteblume mobile phone app, developed Germany facilitate rhinitis. Methods We evaluated...
Web-based lifestyle interventions have attracted considerable research interest. Available evidence on such suggests health-promoting effects, but further is needed. Therefore, this study aims to investigate short-, medium-, and long-term health effects of a web-based program ("TK-HealthCoach", TK-HC) offered by national statutory insurance fund (Techniker Krankenkasse, TK). The comprises two randomized controlled clinical trials evaluate the goals "Increasing Fitness" (F
Abstract Background A healthy lifestyle can help prevent diseases that impair quality of life and lead to premature death. The Techniker health insurance fund offers a comprehensive online program support users in achieving their goals Increasing Fitness , Losing Maintaining Weight or Smoking Cessation . Methods aim this study is test the long-term effectiveness web-based TK-HealthCoach with regard primary outcomes increased physical activity, sustainable weight reduction, smoking...
4142 Background: Both X and T have single agent activity in upper gastrointestinal tumors, together demonstrated preclinical synergy a survival benefit breast cancer. Phase II trials of XT shown response rates 40–53% good tolerability 1st-line metastatic gastric cancer (ASCO 04, abstracts 4051 4057). This trial assessed the efficacy feasibility combination patients (pts) with MEC. Methods: Pts received 75mg/m2 day 1 plus oral 1000mg/m2 twice d1–14 every 3 weeks. The primary endpoint was...
This study assessed the value of (18)F-deoxyglucose positron emission tomography (FDG-PET) for visualisation and early metabolic response assessment in metastatic gastro-oesophageal cancer.Twenty-six patients who were treated disease (20 adenocarcinomas, 6 squamous cell cancers) underwent FDG-PET before two weeks after onset palliative chemotherapy with either oxaliplatin + 5-FU/LV or docetaxel capecitabine. PET results validated according to clinical based on RECIST criteria.Twenty-four...
4016 Background: Phase II trials of biweekly oxaliplatin-5FU protocols demonstrated activity in MGC (Louvet, JCO 2002; Al-Batran, 2004). This trial assessed the efficacy a weekly protocol which has shown high metastatic colorectal cancer (Grothey, ASCO 2002 abstract 512). Methods: Pts received oxaliplatin 50mg/m2 plus 5FU 2000mg/m2 DL-folinic acid 500mg/m2 d1,8,15,22 qd36. The primary endpoint was response according to RECIST. Toxicity reported NCI.CTC v2.0. Median follow-up is 18.1...